Powder: -20°C for 3 years | In solvent: -80°C for 1 year
3BDO is a new mTOR activator. 3BDO inhibits autophagy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 63.00 | |
10 mg | In stock | $ 98.00 | |
25 mg | In stock | $ 219.00 | |
50 mg | In stock | $ 349.00 | |
100 mg | In stock | $ 547.00 | |
200 mg | In stock | $ 817.00 | |
500 mg | In stock | $ 1,250.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 68.00 |
Description | 3BDO is a new mTOR activator. 3BDO inhibits autophagy. |
In vitro | Phosphorylation of RPS6KB1 and EIF4EBP1 is significantly increased by 3BDO with vector alone but suppressed with FKBP1A overexpression. Rapamycin fails to decrease the phosphorylation of MTOR and RPS6KB1 in the presence of 3BDO. 3BDO suppresses the increase in MAP1LC3B puncta induced with rapamycin. 3BDO also inhibits the effect of rapamycin in HUVECs. The phosphorylation of Ser residues is decreased in HUVECs treated with 10 μM rapamycin, and 60 μM 3BDO reverses the phosphorylation. The results show that 3BDO suppresses the increased MAP1LC3B puncta number, MAP1LC3B-II level and decreased SQSTM1 protein level induced by rapamycin. 3BDO could dose- and time-dependently decrease FLJ11812 level in HUVECs. Overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO[1]. |
In vivo | Immunofluorescence assay demonstrates that treatment with 3BDO enhances p-p70S6K levels while reducing ATG13 protein levels in the plaque endothelium of mice, without affecting the phosphorylation of mTOR's immediate downstream targets p70S6K and 4EBP1. Comparatively, in apoE-/- mice, 3BDO treatment notably inhibits endothelium autophagy and apoptosis, thereby offering protection against endothelial injury in atherosclerosis. Furthermore, 3BDO treatment contributes to the stabilization of established atherosclerotic lesions in apoE-/- mice and results in a significant reduction in the serum levels of IL-6 and IL-8. |
Molecular Weight | 327.33 |
Formula | C18H17NO5 |
CAS No. | 890405-51-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (458.25 mM)
Ethanol: 20 mg/mL (61.10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
3BDO 890405-51-3 Apoptosis Autophagy PI3K/Akt/mTOR signaling mTOR Mammalian target of Rapamycin Inhibitor inhibit inhibitor